| NCT03772028 | III | Newly diagnosed stage III ovarian cancer eligible for primary cytoreductive surgery | Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy | NY | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | HIPEC | Hyperthermic Intraperitoneal Chemotherapy | | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04095364 | III | Newly diagnosed stage II-IV low grade serous ovarian cancer without mutations in TP53 | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum | AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WV, WI, WY | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04498117 | III | Newly diagnosed stage III/IV ovarian cancer without BRCA1/2 mutations following optimal cytoreduction at primary or interval surgery | A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma | AZ, CA, CO, CT, FL, GA, HI, IL, IN, LA, MA, MI, MN, NE, NH, NJ, NY, NC, OH, OK, OR, PA, RI, SD, TN, TX, VA, WA, WI | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Oregovomab | OvaRex, Monoclonal Antibody B43.13, B43.13 | Immune response against cancer expressing CA125 | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05446870 | II | Newly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant) | A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer | CO, FL, IL, MO, NJ, NY, SD | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | MK-4830 | anti-ILT4 monoclonal antibody MK-4830 | Blocks ILT4 inhibition of immune cells | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04606914 | II | Newly diagnosed stage III/IV high grade serous FRalpha high+ ovarian cancer (neo-adjuvant) | Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive | AL | View Drugs | View Results |
|
|
| NCT04082572 | II | Newly diagnosed advanced solid tumors with dMMR or high MSI | Neoadjuvant Pembrolizumab for Patients With Mismatch Repair Deficient Locally Advanced Solid Cancers | TX | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05739981 | II | Newly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant and maintenance) | A Phase II Study Evaluating the Effect of GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) on Second Look Laparoscopy (SLL) When Administered in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Subjects Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | TX | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | GEN-1 | phIL-12-005/PPC, EGEN-001, PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, IMNN-001 | IL-12R agonist | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03574779 | II | Platinum resistant ovarian cancer or Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) | A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL) | CA, IL, ME, MA, MN, OK, SD, WA | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05276973 | I/Ib | Newly diagnosed stage III/IV high grade serous or high grade endometrioid ovarian cancer (neo-adjuvant) | Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805 | GA, OH, OK, RI, VA, WI | View Drugs | |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05145569 | I | Newly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant) | A Phase 1b, Open-Label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy With or Without BINTRAFUSP ALFA in Patients With Metastatic Advanced Stage Ovarian Cancer | PA | View Drugs | View Results |
Bintrafusp alfa | MSB0011359C, M7824 | TGFbeta trap and blocks PD-L1 inhibition of T cells | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04024878 | I | Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) or platinum sensitive recurrent ovarian cancer (at first recurrence) (neo-adjuvant or adjuvant and maintenance) | NeoVax With Nivolumab in Patients With Ovarian Cancer | MA | View Drugs | |
NeoVax | | Immune response against neoantigens | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03943173 | I | Newly diagnosed ovarian cancer with BRCA1/2 mutations (neo-adjuvant) | NOW: Neoadjuvant Olaparib Window Trial in Newly Diagnosed BRCA-Mutant Ovarian Cancer | TX | View Drugs | View Results |
|
|
| NCT04847063 | I | Newly diagnosed or recurrent ovarian cancer with peritoneal disease | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | MD | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers | HIPEC | Hyperthermic Intraperitoneal Chemotherapy | | NCCN Guidelines for Ovarian Cancer | Oxaliplatin | OHP, Eloxatine, Dacplat, Dacotin, Eloxatin | DNA damaging agent | | Surgery | | | Clinical Trials |
|
|